Evidence map›Paper›PMID 37732993›Full record

ArticleGlobal health action2023

Quality of active case-finding for tuberculosis in India: a national level secondary data analysis.

Hemant Deepak Shewade, G Kiruthika, Prabhadevi Ravichandran, Swati Iyer, Aniket Chowdhury, S Kiran Pradeep, Kathiresan Jeyashree, S Devika, Joshua Chadwick, Jeromie Wesley Vivian and 8 more

Abstract read
In one paragraph

Article in Global health action, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Hemant Deepak ShewadeDivision of Health Systems Research, ICMR-National Institute of Epidemiology (ICMR-NIE), Chennai, India.
G KiruthikaDivision of Epidemiology and Biostatistics, ICMR-National Institute of Epidemiology (ICMR-NIE), Chennai, India.
Prabhadevi RavichandranDivision of Health Systems Research, ICMR-National Institute of Epidemiology (ICMR-NIE), Chennai, India.ORCID 0000-0001-9221-2251
Swati IyerTuberculosis, Office of the World Health Organization (WHO) Representative to India, New Delhi, India.
Aniket ChowdhuryTuberculosis, Office of the World Health Organization (WHO) Representative to India, New Delhi, India.
S Kiran PradeepDivision of Health Systems Research, ICMR-National Institute of Epidemiology (ICMR-NIE), Chennai, India.
Kathiresan JeyashreeDivision of Epidemiology and Biostatistics, ICMR-National Institute of Epidemiology (ICMR-NIE), Chennai, India.
S DevikaDivision of Epidemiology and Biostatistics, ICMR-National Institute of Epidemiology (ICMR-NIE), Chennai, India.
Joshua ChadwickSchool of Public Health, ICMR-National Institute of Epidemiology (ICMR-NIE), Chennai, India.
Jeromie Wesley VivianDivision of Epidemiology and Biostatistics, ICMR-National Institute of Epidemiology (ICMR-NIE), Chennai, India.
Dheeraj TumuTuberculosis, Office of the World Health Organization (WHO) Representative to India, New Delhi, India.
Amar N ShahHealth Office, USAID India, New Delhi, India.
Bhavin VaderaHealth Office, USAID India, New Delhi, India.
Venkatesh RoddawarTIFA project, John Snow India Private Ltd, New Delhi, India.
Sanjay K MattooCentral TB Division, Ministry of Health and Family Welfare, New Delhi, India.
Kiran RadeTuberculosis, Office of the World Health Organization (WHO) Representative to India, New Delhi, India.
Raghuram RaoCentral TB Division, Ministry of Health and Family Welfare, New Delhi, India.
Manoj V MurhekarDivision of Epidemiology and Biostatistics, ICMR-National Institute of Epidemiology (ICMR-NIE), Chennai, India.

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundIndia has been implementing active case-finding (ACF) for TB among marginalised and vulnerable (high-risk) populations since 2017. The effectiveness of ACF cycle(s) is dependent on the use of appropriate screening and diagnostic tools and meeting quality indicators.

objectivesTo determine the number of ACF cycles implemented in 2021 at national, state (

methodsIn this descriptive study, aggregate TB program data for each ACF activity that was extracted was further aggregated against each ACF cycle at the district level in 2021. One ACF cycle was the period identified to cover all the high-risk populations in the district. Three TB ACF quality indicators were calculated: percentage population screened (≥10%), percentage tested among screened (≥4.8%) and percentage diagnosed among tested (≥5%). We also calculated the number needed to screen (NNS) for diagnosing one person with TB (≤1538).

resultsOf 768 TB districts, ACF data for 111 were not available. Of the remaining 657 districts, 642 (98%) implemented one, and 15 implemented two to three ACF cycles. None of the districts or states met all three TB ACF quality indicators' cut-offs. At the national level, for the first ACF cycle, 9.3% of the population were screened, 1% of the screened were tested and 3.7% of the tested were diagnosed. The NNS was 2824: acceptable (≤1538) in institutional facilities and poor for population-based groups. Data were not consistently available to calculate the percentage of i) high-risk population covered, ii) presumptive TB among screened and iii) tested among presumptive.

conclusionIn 2021, India implemented one ACF cycle with sub-optimal ACF quality indicators. Reducing the losses between screening and testing, improving data quality and sensitising stakeholders regarding the importance of meeting all ACF quality indicators are recommended.

Indexed as

Secondary Data AnalysisTuberculosisData AccuracyHealth FacilitiesHumansIndiahigh-risk groupsIndianumber needed to screenOperational researchTB ACF cycleTB ACF quality indicators

Identifiers

PMID37732993
PMCPMC10515680

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.